Autolus TherapeuticsFRA:6A3A 67 Forward Dividend Yield % is 0.00% as of Jul. 07, 2026. GuruFocus rates FRA:6A3A with a GF Score™ of 67/100 and a GF Value™ of €15.81 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 147 Biotechnology companies, Autolus Therapeutics ranks worse than 680271.43% on this metric.
As of today (2026-07-07), the Forward Annual Dividend Yield of Autolus Therapeutics is 0.00%.
As of today (2026-07-07), the Trailing Annual Dividend Yield of Autolus Therapeutics is 0.00%.
FRA:6A3A's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.3 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Autolus Therapeutics Forward Dividend Yield % Related Terms
FRA:6A3A vs FBRX, SGMT, EDIT: Forward Dividend Yield % Comparison
For the Biotechnology subindustry, Autolus Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Autolus Therapeutics Forward Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Autolus Therapeutics's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Autolus Therapeutics's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Autolus Therapeutics (FRA:6A3A) has a Forward Dividend Yield % of 0.00% as of Jul. 07, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Autolus Therapeutics and its competitors. According to the industry distribution chart, Autolus Therapeutics ranks #999999 out of 147 companies in the Biotechnology industry.
Is Autolus Therapeutics' Forward Dividend Yield % too high?
Autolus Therapeutics' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Autolus Therapeutics ranks #999999 out of 147 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Autolus Therapeutics has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Autolus Therapeutics' Forward Dividend Yield % compare to FBRX and SGMT?
According to the Biotechnology industry distribution chart, Autolus Therapeutics ranks #999999 out of 147 companies for Forward Dividend Yield %. This places Autolus Therapeutics in the lower half of its industry. The industry median Forward Dividend Yield % is 1.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.30, based on 147 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Autolus Therapeutics and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autolus Therapeutics's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autolus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Autolus Therapeutics (FRA:6A3A) is currently considered Possible Value Trap. The stock's GF Value™ is €15.81, compared to a current price of €1.37 — trading 91.3% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Autolus Therapeutics' overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Autolus Therapeutics (FRA:6A3A), the current Forward Dividend Yield % is 0.00% as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Autolus Therapeutics (FRA:6A3A) Overvalued in 2026?
Based on GuruFocus' analysis, Autolus Therapeutics stock appears to be undervalued.
The current stock price of €1.37 is trading 91.3% below its estimated GF Value™ of €15.81.
GuruFocus considers Autolus Therapeutics to be Possible Value Trap.
Key valuation signals for FRA:6A3A:
Forward Dividend Yield %: 0.00%
GF Value™: €15.81 vs. price of €1.37 (91.3% below fair value)
No single metric tells the full story. See the FRA:6A3A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
67GF Score
Get the complete analysis for FRA:6A3A
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6A3A has been successfully added to your 